Literature DB >> 18024789

S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors.

Mark J Millan1, Clotilde Mannoury la Cour, Francesca Novi, Roberto Maggio, Valérie Audinot, Adrian Newman-Tancredi, Didier Cussac, Valérie Pasteau, Jean-A Boutin, Thierry Dubuffet, Gilbert Lavielle.   

Abstract

The novel, potential antipsychotic, S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide), displayed approximately 25-fold higher affinity at human (h) dopamine D(3) versus hD(2L) (long isoform) and hD(2S) (short isoform) receptors (pK(i) values, 8.7, 7.1, and 7.3, respectively). Conversely, haloperidol, clozapine, olanzapine, and risperidone displayed similar affinities for hD(3), hD(2L), and hD(2S) sites. In guanosine-5'-O-(3-[(35)S]thio)-triphosphate ([(35)S]-GTPgammaS) filtration assays, S33138 showed potent, pure, and competitive antagonist properties at hD(3) receptors, displaying pK(B) and pA(2) values of 8.9 and 8.7, respectively. Higher concentrations were required to block hD(2L) and hD(2S) receptors. Preferential antagonist properties of S33138 at hD(3) versus hD(2L) receptors were underpinned in antibody capture/scintillation proximity assays (SPAs) of Galpha(i3) recruitment and in measures of extracellular-regulated kinase phosphorylation. In addition, in cells cotransfected with hD(3) and hD(2L) receptors that assemble into heterodimers, S33138 blocked (pK(B), 8.5) the inhibitory influence of quinpirole upon forskolin-stimulated cAMP formation. S33138 had low affinity for hD(4) receptors (<5.0) but revealed weak antagonist activity at hD(1) receptors (Galphas/SPA, pK(B), 6.3) and hD(5) sites (adenylyl cyclase, 6.5). Modest antagonist properties were also seen at human serotonin (5-HT)(2A) receptors (Galpha(q)/SPA, pK(B), 6.8, and inositol formation, 6.9) and at 5-HT(7) receptors (adenylyl cyclase, pK(B), 7.1). In addition, S33138 antagonized halpha(2C) adrenoceptors ([(35)S]GTPgammaS, 7.2; Galpha(i3)/SPA, 6.9; Galpha(o)/SPA, 7.3, and extracellular-regulated-kinase, 7.1) but not halpha(2A) or halpha(2B) adrenoceptors (<5.0). Finally, in contrast to haloperidol, clozapine, olanzapine, and risperidone, S33138 displayed negligible affinities for multiple subtypes of alpha(1)-adrenoceptor, muscarinic, and histamine receptor. In conclusion, S33138 possesses a distinctive receptor-binding profile and behaves, in contrast to clinically available antipsychotics, as a preferential antagonist at hD(3) versus hD(2) receptors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18024789     DOI: 10.1124/jpet.107.126706

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  16 in total

Review 1.  Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models.

Authors:  L Lyon; L M Saksida; T J Bussey
Journal:  Psychopharmacology (Berl)       Date:  2011-11-10       Impact factor: 4.530

Review 2.  Rationale in support of the use of selective dopamine D₃ receptor antagonists for the pharmacotherapeutic management of substance use disorders.

Authors:  Christian Heidbreder
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-10-28       Impact factor: 3.000

3.  The effects of the preferential dopamine D(3) receptor antagonist S33138 on ethanol binge drinking in C57BL/6J mice.

Authors:  Onarae V Rice; Jay Patrick; Charles D Schonhar; Haoran Ning; Charles R Ashby
Journal:  Synapse       Date:  2012-06-20       Impact factor: 2.562

4.  Selective blockade of dopamine D3 receptors enhances while D2 receptor antagonism impairs social novelty discrimination and novel object recognition in rats: a key role for the prefrontal cortex.

Authors:  David J G Watson; Florence Loiseau; Manuela Ingallinesi; Mark J Millan; Charles A Marsden; Kevin C F Fone
Journal:  Neuropsychopharmacology       Date:  2011-10-26       Impact factor: 7.853

Review 5.  Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders.

Authors:  Christian A Heidbreder; Amy H Newman
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

Review 6.  Beyond small-molecule SAR: using the dopamine D3 receptor crystal structure to guide drug design.

Authors:  Thomas M Keck; Caitlin Burzynski; Lei Shi; Amy Hauck Newman
Journal:  Adv Pharmacol       Date:  2014

7.  The tetrahydroisoquinoline derivative SB269,652 is an allosteric antagonist at dopamine D3 and D2 receptors.

Authors:  Elena Silvano; Mark J Millan; Clotilde Mannoury la Cour; Yang Han; Lihua Duan; Suzy A Griffin; Robert R Luedtke; Gabriella Aloisi; Mario Rossi; Francesca Zazzeroni; Jonathan A Javitch; Roberto Maggio
Journal:  Mol Pharmacol       Date:  2010-08-11       Impact factor: 4.436

8.  Y-QA31, a novel dopamine D3 receptor antagonist, exhibits antipsychotic-like properties in preclinical animal models of schizophrenia.

Authors:  Xue Sun; Hong-yan Gou; Fei Li; Guan-yi Lu; Rui Song; Ri-fang Yang; Ning Wu; Rui-bin Su; Bin Cong; Jin Li
Journal:  Acta Pharmacol Sin       Date:  2016-01-18       Impact factor: 6.150

9.  The preferential dopamine D3 receptor antagonist S33138 inhibits cocaine reward and cocaine-triggered relapse to drug-seeking behavior in rats.

Authors:  Xiao-Qing Peng; Charles R Ashby; Krista Spiller; Xia Li; Jie Li; Nitza Thomasson; Mark J Millan; Elisabeth Mocaër; Carmen Muńoz; Eliot L Gardner; Zheng-Xiong Xi
Journal:  Neuropharmacology       Date:  2009-03       Impact factor: 5.250

Review 10.  Dopamine D₃ receptor antagonism--still a therapeutic option for the treatment of schizophrenia.

Authors:  Gerhard Gross; Karsten Wicke; Karla U Drescher
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-11-06       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.